A phase II trial indicated that the combination of trastuzumab, nivolumab (a PD-1 inhibitor), and FOLFOX chemotherapy significantly improved overall survival (OS) in HER2-positive gastric cancer (GC) patients (21.8 months vs. 16.4 months) (31). This evidence concerns the gene ERBB2 and gastric cancer.